Glancy Prongay & Murray LLP Commences Investigation on Behalf of Fresenius Medical Care AG & Co. KGAA Investors

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Fresenius Medical Care AG & Co. KGAA ("Fresenius" or the "Company") FMS investors concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of Fresenius investors.

Fresenius is a kidney dialysis company that provides dialysis treatment and related dialysis care services, and other health care services.

On January 7, 2017, Fresenius disclosed that it was in receipt of subpoenas from federal prosecutors in connection with the Company's relationship with the American Kidney Fund, a charity that provides financial aid to patients for kidney dialysis.

On this news, Fresenius stock has fallen as much as 6.70%, to $39.70 during intra-day trading on January 9, 2017.

If you purchased Fresenius securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170109006418/en/